Document Classification

Section Type: RESULTS

Text: Treatment with FP significantly increased the mean change at endpoint (the last post-baseline observation) in FEV1 (0. 22 L versus 0. 03 L, P <. 001), morning PEF (17. 8 versus 3. 1 L/min, P =. 004), evening PEF (16. 7 versus 2. 6 L/min, P =. 002), the percentage of symptom-free days (16. 2 versus 7. 1 %, P =. 007), and the percentage of rescue-free days (23. 4 versus 9. 3 %, P <. 001), and significantly decreased rescue albuterol use (-0. 66 puffs/day versus an increase of 0. 27 puffs/day, P <. 001) and combined symptom scores (-0. 13 versus an increase of 0. 08, P <. 001) compared with zafirlukast.